CEACAM5 and metastatic malignant neoplasm in the lymph nodes: It is somewhat puzzling that the positive rate of CEA mRNA in the validation set (23.3%) was lower than that of the training set (27.9%), although the validation set presented a higher incidence of patients with ‘classical’ adverse prognostic factors such as serosal invasion and/or lymph node metastases.